- Home
- UFPI vs LEGN Comparison
UFPI vs LEGN Comparison
Compare UFPI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFPI
- LEGN
- Stock Information
- Founded
- UFPI 1955
- LEGN 2014
- Country
- UFPI United States
- LEGN United States
- Employees
- UFPI N/A
- LEGN N/A
- Industry
- UFPI Forest Products
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- UFPI Basic Materials
- LEGN Health Care
- Exchange
- UFPI Nasdaq
- LEGN Nasdaq
- Market Cap
- UFPI 6.0B
- LEGN 7.0B
- IPO Year
- UFPI 1993
- LEGN 2020
- Fundamental
- Price
- UFPI $97.37
- LEGN $31.78
- Analyst Decision
- UFPI Strong Buy
- LEGN Strong Buy
- Analyst Count
- UFPI 4
- LEGN 13
- Target Price
- UFPI $143.00
- LEGN $79.42
- AVG Volume (30 Days)
- UFPI 480.5K
- LEGN 1.5M
- Earning Date
- UFPI 04-28-2025
- LEGN 05-13-2025
- Dividend Yield
- UFPI 1.44%
- LEGN N/A
- EPS Growth
- UFPI N/A
- LEGN N/A
- EPS
- UFPI 6.11
- LEGN N/A
- Revenue
- UFPI $6,608,862,000.00
- LEGN $627,241,000.00
- Revenue This Year
- UFPI $4.05
- LEGN $65.96
- Revenue Next Year
- UFPI $5.89
- LEGN $52.55
- P/E Ratio
- UFPI $15.88
- LEGN N/A
- Revenue Growth
- UFPI N/A
- LEGN 119.97
- 52 Week Low
- UFPI $95.90
- LEGN $29.27
- 52 Week High
- UFPI $141.33
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- UFPI 38.28
- LEGN 41.49
- Support Level
- UFPI $95.90
- LEGN $30.25
- Resistance Level
- UFPI $99.77
- LEGN $35.81
- Average True Range (ATR)
- UFPI 2.71
- LEGN 1.45
- MACD
- UFPI -0.56
- LEGN -0.18
- Stochastic Oscillator
- UFPI 10.55
- LEGN 27.58
About UFPI UFP Industries Inc.
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.